secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-062026
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Q3 revenue $40.8M (+23% YoY); FY2023 guidance cut to $182-186M from $191-197M
--------------------------------------------------------------------------------

- Q3 revenue $40.8M (+23% YoY) driven by higher kit volume and record ASP of $6,311.
- Net loss widened to $17.5M ($0.28/sh) from $12.1M ($0.22/sh) in Q3 2022.
- Adjusted EBITDA loss of $9.2M vs $8.6M loss a year ago; expects positive adj. EBITDA in Q4.
- Full-year 2023 revenue guidance lowered to $182-186M (28-31% growth) from $191-197M.
- Surgeon base grew 21% to 2,691; new technologies launched including Gen 2 SpeedPlate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000095017023062026/0000950170-23-062026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000095017023062026/tmci-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer